
Dave Wallace, Generics Bulletin executive editor
@DaveGenerics
Followers
130
Following
11
Media
2
Statuses
129
Generics Bulletin editor Dave Wallace looks at everything that's important to the generics, biosimilars and value-added medicines industries. All views my own.
Joined March 2019
In this exclusive two-part interview, @Amgen's Chad Pettit, @AmgenBiosim commercial lead, talks to @Genericbulletin about the firm’s “unique perspective” on biosimilars, including how competition to Humira is expected to signal a major shift in the US biosimilars landscape.
0
2
1
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, says AmerisourceBergen’s (@Healthcare_ABC’s) senior vice president for global emerging therapies and channel strategy, Beth McMahon.
0
4
2
In an exclusive two-part interview, @SamsungBioepis development division leader Kyung-ah Kim and @biogen global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.
0
1
2
In this two-part interview, I talk to @hikmapharma CEO Siggi Olafsson about how Hikma expects to maintain its deal-making momentum, future plans for US biosimilars, and how it is positioned to deal with pricing pressures and increased competition on some of its key generics.
0
0
1
Sonia Oskouei, @cardinalhealth VP of biosimilars, talks about how real-world evidence and education can build confidence in biosimilars, as well as the ongoing struggle against misinformation and need for clarity over concepts such as interchangeability and unbranded biologics.
0
1
1
RT @AccessibleMeds: In this @Pharma_Intell interview, #AAMBoard Vice Chair Christine Baeder (Senior Vice President, Chief Operating Officer….
0
2
0
A major biosimilars deal between @Bioconlimited and @ViatrisInc to kick off this week:.
0
0
0
With key milestones on the horizon for US biosimilars in 2022 and 2023, @cardinalhealth VP of biosimilars Sonia Oskouei explains how the industry can best position itself to take advantage of upcoming opportunities, including potentially a global leadership role in ophthalmology.
0
0
0
RT @USBiosimilars: Biosimilars Forum executive director Juliana Reed discusses the Forum's priorities and leadership in the #biosimilars in….
0
1
0
In an exclusive interview with Generics Bulletin, the @USBiosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.
0
2
4
RT @RobertWessman: This is the first part of an exclusive two-part interview with David Wallace at @Genericbulletin, where I talk about Alv….
0
1
0
In the second part of an exclusive two-part interview with Generics Bulletin, @alvotechpr founder and chairman @RobertWessman sets out the firm’s expectations for its rival to Humira as it continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.
0
0
1
Alvotech founder and chairman @RobertWessman tells Generics Bulletin how the firm plans to move forward following recently-revealed plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. @alvotechpr.
0
0
0
With the first approved rival to Lucentis in both the EU and US, @SamsungBioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.
0
0
0
With the Big Give, @ihp_uk is raising money to get vital medicine to people who need it. For every £1 donated, IHP can send £20 worth of medicine. .
The @BigGive #ChristmasChallenge21 ends in 24 hours. We still have about £10,000 of match funding still available! We need your help urgently to make double the difference to the lives of people who lack access to medicine around the world:
0
0
1
In this interview, CEO Michael Goettler provides an update on the progress made by @ViatrisInc in its first year, also previewing the detailed strategy that will be unveiled at the firm’s upcoming investor day and underlining the importance of biosimilars and complex generics.
0
0
0
RT @ihp_uk: Thanks for a great night at the #GGBAwards. A big shout out to all the entries for this year’s #CSR Initiative of the Year awa….
0
2
0